1.Assessment of antiangiogenic therapy in a nude murine hepatocellular carcinoma model with real-time gray-scale contrast-enhanced ultrasonography
Peili FAN ; Hong DING ; Xiaodong ZHU ; Xiyuan LIN ; Jubo ZHANG ; Wenping WANG ; Huichuan SUN
Chinese Journal of Ultrasonography 2009;18(8):708-712
ular perfusion in tumors objectively, which is potential in monitoring tumor vascular response to antiangiogenic therapy.
2.Correlation of transcription factor Sp1 expression with clinical and pathological characteristics and prognosis of hepatocellular carcinoma
Qi PAN ; Kai ZHU ; Wanyong CHEN ; Jubo ZHANG ; Huichuan SUN ; Lu WANG ; Ning REN
Chinese Journal of Clinical Oncology 2014;(20):1284-1287
Objective: To explore the clinical significance of transcription factor Sp1 expression in hepatocellular carcinoma (HCC) and association between Sp1 expression and survival in HCC patients. Methods:With the use of immunoreactivity, Sp1 expres-sion and its correlation with other clinicopathological characteristics were examined in a tissue microarray that contains samples from 98 HCC patients. Results:HCC tissues expressed markedly higher levels of Sp1 than did adjacent normal liver tissues. Sp1 expression was closely associated with microvascular invasion, which suggests that HCC with more microvascular invasion is prone to have in-creased Sp1 expression. Overexpression of Sp1 correlates with significantly shorter overall survival and higher recurrence rates in HCC patients after curative resection. Conclusion:Transcription factor Sp1 may be an independent prognostic factor for both overall surviv-al and cumulative recurrence rate.
3.Analysis of Historical Evolution and Current Situation of Approval System for Marketing Application of New Chemical Pharmaceuticals in China
Xuan WANG ; Jubo LIU ; Wentao ZHU
China Pharmacist 2018;21(2):314-317
Objective:To review the historical evolution and current situation of approval system for marketing application of new chemical pharmaceuticals in China to provide reference for the establishment of more perfect approval system. Methods: Through clearing up the historical evolution of approval regulations for marketing application and combining with the current approval system,the development track of the regulatory system from the vulgar administration gradually transferring to the scientific management was ana-lyzed comprehensively. Results and Conclusion: The dividend of current approval system has appeared, meanwhile, the constantly improving process will lay the foundation for setting up the regulatory system conforming to the situation of China and in line with inter-national standards.
4.A case of successful transcatheter aortic valve implantation for severe noncalcified aortic regurgitation.
Xianbao LIU ; Liang DONG ; Jubo JIANG ; Qijing ZHOU ; Wei HE ; Zhaoxia PU ; Liming ZHOU ; Zhaoxu HUANG ; Yan FENG ; Minjian KONG ; Yinghong HU ; Yong SUN ; Jun JIANG ; Youqi FAN ; Aiqiang DONG ; Min YAN ; Jianan WANG
Chinese Journal of Cardiology 2015;43(2):185-186
5.Clinical practice and prognosis of emergent transcatheter aortic valve replacement
Dao ZHOU ; Xianbao LIU ; Jiaqi FAN ; Lihan WANG ; Po HU ; Jubo JIANG ; Zhaoxia PU ; Xinping LIN ; Huajun LI ; Hanyi DAI ; Gangjie ZHU ; Yeming XU ; Jian’an WANG
Chinese Journal of Emergency Medicine 2022;31(3):368-373
Objective:To evaluate the effectiveness and prognosis of emergent transcatheter aortic valve replacement (TAVR) and to provide standardized procedural suggestion for the development of emergent TAVR in China.Methods:From January 2020 to April 2021, 12 patients who underwent emergent or salvage TAVR in the Second Affiliated Hospital Zhejiang University School of Medicine were retrospectively enrolled from the TORCH registry (Transcatheter Aortic Valve Replacement Single Center Registry in Chinese Population, a prospective cohort study; NCT02803294). Baseline, periprocedural and 30-day follow up data were collected. Post-operative data were compared with pre-operative data using Paired-Samples test.Results:Patients’ median Society of Thoracic Surgeons score (STS score) was 15.432%. There was a significant decrease of mean gradient after emergent TAVR procedure (1.69 m/s vs. 4.90 m/s, P<0.01). During the 30-day follow up, there were 1 patient (8.3%) died and 2 patients received permanent pacemaker implantation. No disabling stroke, acute kidney injury, major vascular complication occurred during the first month after emergent TAVR. Among the survival patients, there was a significant releasing of heart failure symptoms to New York Heart Association function stage Ⅰ/Ⅱ in 81.8% patients at 30-day follow up. Left ventricular ejection fraction also improved significantly from (47.4±9.5)% to 58.8±8.0% ( P= 0.026). The mean gradient were (1.57±0.30) cm 2 and no patients had a moderate or severe paravalvular leakage. Besides, a significant decrease of pro-B-type natriuretic peptide (1 089.9 pg/mL vs. 12 215.5 pg/mL , P=0.001) and troponin T (0.020 ng/mL vs. 0.337 ng/mL, P=0.003) were found at 30 days after emergent TAVR. Conclusions:For patients with severe aortic stenosis and acute cardiac decompensated, emergent TAVR is a safe and effective rescue treatment.
6. Effect of primary prevention program for stroke in rural areas of Shanghai
Jiping GUO ; Jiuyi HUANG ; Qinghua CHEN ; Haiying CHEN ; Jubo FEI ; Yan WANG ; Yongju YANG ; Yifeng CAO ; Zhenmao GU
Chinese Journal of Health Management 2020;14(1):15-20
Objective:
This study aimed to analyze and summarize the implementation of the primary prevention program for stroke in Shanghai rural community and evaluate its preventive effect.
Methods:
A cluster sampling method was used to select approximately 50 000 community natural population from a town in Fengxian District of Shanghai. A primary stroke prevention program was established and implemented in the community from 2008 to 2010 and from 2012 to 2015. The prevention program inclueded stroke
7.Preparing anti-SARS-CoV-2 agent EIDD-2801 by a practical and scalable approach, and quick evaluation
Zhen QIN ; Bin DONG ; Renbing WANG ; Dechun HUANG ; Jubo WANG ; Xi FENG ; Jinlei BIAN ; Zhiyu LI
Acta Pharmaceutica Sinica B 2021;11(11):3678-3682
EIDD-2801 is an orally bioavailable prodrug, which will be applied for emergency use authorization from the U.S. Food and Drug Administration for the treatment of COVID-19. To investigate the optimal parameters, EIDD-2801 was optimized
8.Kidney function change after transcatheter aortic valve replacement in patients with diabetes and/or hypertension.
Jiaqi FAN ; Changjie YU ; Kaida REN ; Wanbing LIN ; Stella NG ; Zexin CHEN ; Xinping LIN ; Lihan WANG ; Qifeng ZHU ; Yuxin HE ; Jubo JIANG ; Xianbao LIU ; Jian'an WANG
Journal of Zhejiang University. Science. B 2021;22(3):241-247